Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Dose De-Escalation in Prostate Cancer
NCT05276492Phase 1Terminated
- Sponsor
- University of Chicago
- Start
- Jan 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Abiraterone Acetate Tablets (I) in prostate cancer (PCa) (4 arms), sponsored by University of Chicago. Primary endpoint: Change in DHEA-S Levels at 4 weeks. Started Jan 2023; status: terminated.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05276492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276492.